Esomeprazole Magnesium; Naproxen Patent Expiration
Esomeprazole Magnesium; Naproxen is Used for relieving symptoms of arthritis and reducing the risk of NSAID-associated gastric ulcers. It was first introduced by Horizon Medicines Llc
Esomeprazole Magnesium; Naproxen Patents
Given below is the list of patents protecting Esomeprazole Magnesium; Naproxen, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Vimovo | US8945621 | Method for treating a patient at risk for developing an NSAID-associated ulcer | Oct 17, 2031 | Horizon |
| Vimovo | US9220698 | Method for delivering a pharmaceutical composition to patient in need thereof | Mar 10, 2031 | Horizon |
| Vimovo | US9393208 | Method for delivering a pharmaceutical composition to patient in need thereof | Sep 03, 2029 | Horizon |
| Vimovo | US6926907 | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
Feb 28, 2023
(Expired) | Horizon |
| Vimovo | US8557285 | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
May 31, 2022
(Expired) | Horizon |
| Vimovo | US8852636 | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
May 31, 2022
(Expired) | Horizon |
| Vimovo | US8858996 | Pharmaceutical compositions for the coordinated delivery of NSAIDS |
May 31, 2022
(Expired) | Horizon |
| Vimovo | US9161920 | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
May 31, 2022
(Expired) | Horizon |
| Vimovo | US9198888 | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
May 31, 2022
(Expired) | Horizon |
| Vimovo | US9345695 | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
May 31, 2022
(Expired) | Horizon |
| Vimovo | US9707181 | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
May 31, 2022
(Expired) | Horizon |
| Vimovo |
US6369085 (Pediatric) | Form of S-omeprazole |
Nov 25, 2018
(Expired) | Horizon |
| Vimovo |
US7411070 (Pediatric) | Form of S-omeprazole |
Nov 25, 2018
(Expired) | Horizon |
| Vimovo | US7745466 | Form of S-omeprazole |
Oct 13, 2018
(Expired) | Horizon |
| Vimovo | US6369085 | Form of S-omeprazole |
May 25, 2018
(Expired) | Horizon |
| Vimovo | US7411070 | Form of S-omeprazole |
May 25, 2018
(Expired) | Horizon |
| Vimovo |
US5900424 (Pediatric) | Omeprazole magnesium salt form |
Nov 04, 2016
(Expired) | Horizon |
| Vimovo | US5900424 | Omeprazole magnesium salt form |
May 04, 2016
(Expired) | Horizon |
| Vimovo |
US5714504 (Pediatric) | Compositions |
Aug 03, 2015
(Expired) | Horizon |
| Vimovo | US5714504 | Compositions |
Feb 03, 2015
(Expired) | Horizon |
| Vimovo |
US6875872 (Pediatric) | Compounds |
Nov 27, 2014
(Expired) | Horizon |
| Vimovo | US6875872 | Compounds |
May 27, 2014
(Expired) | Horizon |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Esomeprazole Magnesium; Naproxen's patents.
Latest Legal Activities on Esomeprazole Magnesium; Naproxen's Patents
Given below is the list recent legal activities going on the following patents of Esomeprazole Magnesium; Naproxen.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 19 Jan, 2024 | US9393208 |
| Expire Patent Critical | 08 Jan, 2024 | US9198888 |
| Expire Patent Critical | 27 Nov, 2023 | US9161920 |
| Maintenance Fee Reminder Mailed Critical | 24 Jul, 2023 | US9198888 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 29 Jun, 2023 | US9220698(Litigated) |
| Maintenance Fee Reminder Mailed Critical | 12 Jun, 2023 | US9161920 |
| Expire Patent Critical | 21 Nov, 2022 | US8858996 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 03 Aug, 2022 | US8945621(Litigated) |
| Expire Patent Critical | 01 Aug, 2022 | US7745466(Litigated) |
| Maintenance Fee Reminder Mailed Critical | 06 Jun, 2022 | US8858996 |
Esomeprazole Magnesium; Naproxen's Family Patents
Explore Our Curated Drug Screens
Esomeprazole Magnesium; Naproxen Generic API Manufacturers
Several generic applications have been filed for Esomeprazole Magnesium; Naproxen. The first generic version for Esomeprazole Magnesium; Naproxen was by Dr Reddys Laboratories Ltd and was approved on Sep 27, 2013. And the latest generic version is by Sciegen Pharmaceuticals Inc and was approved on Oct 11, 2023.
Given below is the list of companies who have filed for Esomeprazole Magnesium; Naproxen generic, along with the locations of their manufacturing plants worldwide.
1. ACTAVIS LABS FL INC
Actavis Laboratories Fl Inc has filed for 2 different strengths of generic version for Esomeprazole Magnesium; Naproxen. All of these versions come by the name NAPROXEN AND ESOMEPRAZOLE MAGNESIUM. Given below are the details of the strengths of this generic introduced by Actavis Labs Fl Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 20MG BASE; 500MG | tablet, delayed release | Discontinued | ORAL | N/A | Aug 24, 2022 |
| EQ 20MG BASE; 375MG | tablet, delayed release | Discontinued | ORAL | N/A | Aug 24, 2022 |
2. AJANTA PHARMA LTD
Ajanta Pharma Ltd has filed for 2 different strengths of generic version for Esomeprazole Magnesium; Naproxen. All of these versions come by the name NAPROXEN AND ESOMEPRAZOLE MAGNESIUM. Given below are the details of the strengths of this generic introduced by Ajanta Pharma Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 20MG BASE; 375MG | tablet, delayed release | Prescription | ORAL | AB | Oct 6, 2022 |
| EQ 20MG BASE; 500MG | tablet, delayed release | Prescription | ORAL | AB | Oct 6, 2022 |
Manufacturing Plant Locations New
Ajanta Pharma Ltd's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Ajanta Pharma Ltd as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| India |
| |||
3. DR REDDYS
Dr Reddys Laboratories Ltd has filed for 2 different strengths of generic version for Esomeprazole Magnesium; Naproxen. All of these versions come by the name NAPROXEN AND ESOMEPRAZOLE MAGNESIUM. Given below are the details of the strengths of this generic introduced by Dr Reddys.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 20MG BASE; 375MG | tablet, delayed release | Prescription | ORAL | AB | Feb 18, 2020 |
| EQ 20MG BASE; 500MG
(reference standard) | tablet, delayed release | Prescription | ORAL | AB | Feb 18, 2020 |
4. DR REDDYS LABS LTD
Dr Reddys Laboratories Ltd has filed for 2 different strengths of generic version for Esomeprazole Magnesium; Naproxen. All of these versions come by the name NAPROXEN AND ESOMEPRAZOLE MAGNESIUM. Given below are the details of the strengths of this generic introduced by Dr Reddys Labs Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 20MG BASE; 375MG | tablet, delayed release | Prescription | ORAL | AB | Sep 27, 2013 |
| EQ 20MG BASE; 500MG | tablet, delayed release | Prescription | ORAL | AB | Sep 27, 2013 |
5. MYLAN
Mylan Pharmaceuticals Inc has filed for 2 different strengths of generic version for Esomeprazole Magnesium; Naproxen. All of these versions come by the name NAPROXEN AND ESOMEPRAZOLE MAGNESIUM. Given below are the details of the strengths of this generic introduced by Mylan.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 20MG BASE; 375MG | tablet, delayed release | Discontinued | ORAL | N/A | Jul 20, 2021 |
| EQ 20MG BASE; 500MG | tablet, delayed release | Discontinued | ORAL | N/A | Jul 20, 2021 |
Manufacturing Plant Locations New
Mylan's manufacturing plants are situated in 4 countries - United States, India, Canada, Ireland. Given below are the details of these plant locations as well as the firm names of Mylan as present at those locations.
| Country | City | Firm Name | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||
| India |
| |||||||||||||||||
| Canada |
| |||||||||||||||||
| Ireland |
| |||||||||||||||||
6. SCIEGEN PHARMS INC
Sciegen Pharmaceuticals Inc has filed for 2 different strengths of generic version for Esomeprazole Magnesium; Naproxen. All of these versions come by the name NAPROXEN AND ESOMEPRAZOLE MAGNESIUM. Given below are the details of the strengths of this generic introduced by Sciegen Pharms Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 20MG BASE; 375MG | tablet, delayed release | Prescription | ORAL | AB | Oct 11, 2023 |
| EQ 20MG BASE; 500MG | tablet, delayed release | Prescription | ORAL | AB | Oct 11, 2023 |